Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback